Utility of the Clinical and Radiological Features in the Management of Bethesda 3 and 4 Thyroid Nodules
Indian Journal of Surgical Oncology · 2025-08 · 16 (4) · 882-889
DOI: 10.1007/s13193-024-02167-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Surgical Oncology, online erschienen am 16.12.2024. Verfasst von Shivakumar Thiagarajan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Head & Neck, Department of Surgical Oncology, Tata Memorial Centre and Homi Bhabha National Institute (HBNI), Mumbai, India. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tata Memorial Hospital - TMC.
Abstract (Originalsprache)
Deciding the right treatment strategy for patients with Bethesda 3 and 4 fine needle aspiration cytology (FNAC) reports may be challenging. The reported risk of malignancy (ROM) and those from high-volume institutes may not be identical. The cost of molecular testing and its unavailability for routine use limits its utility in decision-making. In this study, we included all patients diagnosed at our institute with Bethesda 3 and 4 thyroid nodules on FNAC between January 2012 and December 2021. We identified the risk of malignancy for these patients along with other factors that could help identify the possibility of malignancy in these thyroid nodules. We utilised the clinical (C), ultrasound features (U), and the Bethesda category (T) to derive the CUT score and derive a cut-off value beyond which malignancy could be predicted. A total of 359 patients were included in the study. The ROM for the Bethesda 3 thyroid nodule was 77.7% (167/215), and that for the Bethesda 4 thyroid nodule was 76.4% (110/144). On multivariate analysis, nodules taller than wider [0.006, 7.662 (1.806–32.5)], male gender [0.024, 2.359 (1.119–4.976)], and the presence of microcalcification [0.004, 2.328 (1.319–4.109)] were found to be significant for the presence of malignancy in the final histopathology. The CUT score > 8.875 was associated with malignancy in the final histopathology. Various clinical and radiological factors may be useful to identify the nodules harbouring malignancy and facilitate appropriate management. The rate of malignancy in Bethesda 3 and 4 nodules among those who underwent surgery in our cohort was higher.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Head & Neck, Department of Surgical Oncology, Tata Memorial Centre and Homi Bhabha National Institute (HBNI), Mumbai, India.
- Dept. of Pathology, Tata Memorial Centre and Homi Bhabha National Institute (HBNI), Mumbai, India.
- Division of Head & Neck, Dept. of Surgical Oncology, Cancer Institute, Adayar, Chennai India.
- MIOT Hospitals, Chennai, India.
- Department of Radiology, Tata Memorial Centre and Homi Bhabha National Institute (HBNI), Mumbai, India.
ORCID-Profile: Shivakumar Thiagarajan
Förderung
- Tata Memorial Hospital - TMC
Zitieren
APA
Thiagarajan, S., Rane, S., Chandak, K., Gurukeerthi, B., Kantamani, T., Tuljapurkar, V., Kumar, S., & Pantvaidya, G. (2025). Utility of the Clinical and Radiological Features in the Management of Bethesda 3 and 4 Thyroid Nodules. Indian Journal of Surgical Oncology, 16(4), 882-889. https://doi.org/10.1007/s13193-024-02167-7
Vancouver
Thiagarajan S, Rane S, Chandak K, Gurukeerthi B, Kantamani T, Tuljapurkar V, et al. Utility of the Clinical and Radiological Features in the Management of Bethesda 3 and 4 Thyroid Nodules. Indian Journal of Surgical Oncology. 2025;16(4):882-889. doi:10.1007/s13193-024-02167-7
BibTeX
@article{Thiagarajan2025,
author = {Thiagarajan, Shivakumar and Rane, Swapnil and Chandak, Khusbhu and Gurukeerthi, B and Kantamani, Teja and Tuljapurkar, Vidisha and Kumar, Suman and Pantvaidya, Gouri},
title = {Utility of the Clinical and Radiological Features in the Management of Bethesda 3 and 4 Thyroid Nodules},
journal = {Indian Journal of Surgical Oncology},
year = {2025},
volume = {16},
number = {4},
pages = {882--889},
doi = {10.1007/s13193-024-02167-7}
}
EUVIMED